1
|
Wang D, Zhang HX, Yan GJ, Zhao HR, Dong XH, Tan YX, Li S, Lu MN, Mei R, Liu LN, Wang XY, Xiyang YB. Voluntary running wheel exercise induces cognitive improvement post traumatic brain injury in mouse model through redressing aberrant excitation regulated by voltage-gated sodium channels 1.1, 1.3, and 1.6. Exp Brain Res 2024; 242:205-224. [PMID: 37994916 PMCID: PMC10786980 DOI: 10.1007/s00221-023-06734-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Accepted: 10/29/2023] [Indexed: 11/24/2023]
Abstract
Traumatic brain injury (TBI) leads to disturbed brain discharge rhythm, elevated excitability, anxiety-like behaviors, and decreased learning and memory capabilities. Cognitive dysfunctions severely affect the quality of life and prognosis of TBI patients, requiring effective rehabilitation treatment. Evidence indicates that moderate exercise after brain injury decreases TBI-induced cognitive decline. However, the underlying mechanism remains unelucidated. Our results demonstrate that TBI causes cognitive impairment behavior abnormalities and overexpression of Nav1.1, Nav1.3 and Nav1.6 proteins inside the hippocampus of mice models. Three weeks of voluntary running wheel (RW) exercise treatments before or/and post-injury effectively redressed the aberrant changes caused by TBI. Additionally, a 10% exercise-conditioned medium helped recover cell viability, neuronal sodium current and expressions of Nav1.1, Nav1.3 and Nav1.6 proteins across cultured neurons after injury. Therefore, the results validate the neuroprotection induced by voluntary RW exercise treatment before or/and post-TBI. The RW exercise-induced improvement in cognitive behaviors and neuronal excitability could be associated with correcting the Nav1.1, Nav1.3, and Nav1.6 expression levels. The current study proves that voluntary exercise is an effective treatment strategy against TBI. The study also highlights novel potential targets for rehabilitating TBI, including the Navs proteins.
Collapse
Affiliation(s)
- Dan Wang
- Institute of Neuroscience, Faculty of Basic Medical Science, Kunming Medical University, 1168 West Chunrong Road, Yuhua Avenue, Chenggong, Kunming, Yunnan, 650500, People's Republic of China
| | - Hui-Xiang Zhang
- Institute of Neuroscience, Faculty of Basic Medical Science, Kunming Medical University, 1168 West Chunrong Road, Yuhua Avenue, Chenggong, Kunming, Yunnan, 650500, People's Republic of China
| | - Guo-Ji Yan
- Institute of Neuroscience, Faculty of Basic Medical Science, Kunming Medical University, 1168 West Chunrong Road, Yuhua Avenue, Chenggong, Kunming, Yunnan, 650500, People's Republic of China
| | - Hao-Ran Zhao
- Institute of Neuroscience, Faculty of Basic Medical Science, Kunming Medical University, 1168 West Chunrong Road, Yuhua Avenue, Chenggong, Kunming, Yunnan, 650500, People's Republic of China
| | - Xiao-Han Dong
- Institute of Neuroscience, Faculty of Basic Medical Science, Kunming Medical University, 1168 West Chunrong Road, Yuhua Avenue, Chenggong, Kunming, Yunnan, 650500, People's Republic of China
| | - Ya-Xin Tan
- Institute of Neuroscience, Faculty of Basic Medical Science, Kunming Medical University, 1168 West Chunrong Road, Yuhua Avenue, Chenggong, Kunming, Yunnan, 650500, People's Republic of China
- Department of Pediatrics, The People's Liberation Army (PLA) Rocket Force Characteristic Medical Center, Beijing, 100088, China
| | - Shan Li
- Institute of Neuroscience, Faculty of Basic Medical Science, Kunming Medical University, 1168 West Chunrong Road, Yuhua Avenue, Chenggong, Kunming, Yunnan, 650500, People's Republic of China
- Department of Anatomy, Changsha Medical University, Changsha, China
| | - Min-Nan Lu
- Science and Technology Achievement Incubation Center, Kunming Medical University, Kunming, Yunnan, 650500, China
| | - Rong Mei
- Department of Neurology, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China
| | - Li-Na Liu
- Institute of Neuroscience, Faculty of Basic Medical Science, Kunming Medical University, 1168 West Chunrong Road, Yuhua Avenue, Chenggong, Kunming, Yunnan, 650500, People's Republic of China
| | - Xu-Yang Wang
- Department of Neurosurgery, Shanghai Sixth People' Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, People's Republic of China.
| | - Yan-Bin Xiyang
- Institute of Neuroscience, Faculty of Basic Medical Science, Kunming Medical University, 1168 West Chunrong Road, Yuhua Avenue, Chenggong, Kunming, Yunnan, 650500, People's Republic of China.
| |
Collapse
|
2
|
Wei S, Leng B, Yan G. Targeting autophagy process in center nervous trauma. Front Neurosci 2023; 17:1128087. [PMID: 36950126 PMCID: PMC10025323 DOI: 10.3389/fnins.2023.1128087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Accepted: 02/20/2023] [Indexed: 03/08/2023] Open
Abstract
The central nervous system (CNS) is the primary regulator of physiological activity, and when CNS is compromised, its physical functions are affected. Spinal cord injury (SCI) and traumatic brain injury (TBI) are common trauma in CNS that are difficult to recover from, with a higher global disability and mortality rate. Autophagy is familiar to almost all researchers due to its role in regulating the degradation and recycling of cellular defective or incorrect proteins and toxic components, maintaining body balance and regulating cell health and function. Emerging evidence suggests it has a broad and long-lasting impact on pathophysiological process such as oxidative stress, inflammation, apoptosis, and angiogenesis, involving the alteration of autophagy marker expression and function recovery. Changes in autophagy level are considered a potential therapeutic strategy and have shown promising results in preclinical studies for neuroprotection following traumatic brain injury. However, the relationship between upward or downward autophagy and functional recovery following SCI or TBI is debatable. This article reviews the regulation and role of autophagy in repairing CNS trauma and the intervention effects of autophagy-targeted therapeutic agents to find more and better treatment options for SCI and TBI patients.
Collapse
Affiliation(s)
- Shanshan Wei
- Department of Graduate, Shandong Academy of Medical Sciences, Shandong First Medical University, Jinan, China
- Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - Bing Leng
- Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - Genquan Yan
- Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- *Correspondence: Genquan Yan,
| |
Collapse
|
3
|
Abstract
Nitric oxide is an important mediator of vascular autoregulation and is involved in pathophysiological changes after acute neurological disorders. Nitric oxide is generated by nitric oxide synthases from the amino acid L-arginine. L-arginine can also serve as a substrate for arginases or lead to the generation of dimethylarginines, asymmetric dimethylarginine, and symmetric dimethylarginine, by methylation. Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase and can lead to endothelial dysfunction. This review discusses the role of L-arginine metabolism in patients suffering from acute and critical neurological disorders often requiring neuro-intensive care treatment. Conditions addressed in this review include intracerebral hemorrhage, aneurysmal subarachnoid hemorrhage, and traumatic brain injury. Recent therapeutic advances in the field are described including current randomized controlled trials for traumatic brain injuries and hemorrhagic stroke.
Collapse
Affiliation(s)
- Marius Marc-Daniel Mader
- Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA
| | - Patrick Czorlich
- Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
4
|
Chiu LS, Anderton RS, Clark VW, Cross JL, Knuckey NW, Meloni BP. Effect of Polyarginine Peptide R18D Following a Traumatic Brain Injury in Sprague-Dawley Rats. CURRENT THERAPEUTIC RESEARCH 2020; 92:100584. [PMID: 32322314 PMCID: PMC7163064 DOI: 10.1016/j.curtheres.2020.100584] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Accepted: 03/10/2020] [Indexed: 11/23/2022]
Abstract
Cationic arginine-rich peptides (CARPs) have previously demonstrated neuroprotective efficacy in a rat model of traumatic brain injury (TBI). The CARP R18D significantly reduced the extent of axonal injury at a high dose of 1000 nmol/kg. Both high (1000 nmol/kg) and low (100 nmol/kg) doses only showed a trend in functional improvement.
Background Despite extensive studies, there are still no clinically available neuroprotective treatments for traumatic brain injury. Objectives In previous studies we demonstrated beneficial treatment effects of polyarginine peptides R18 (18-mer of arginine; 300 nmol/kg) and R18D (18-mer of D-arginine; 1000 nmol/kg) in a rat model of impact-acceleration closed-head injury. Methods We examined the efficacy of R18D when intravenously administered at a low (100 nmol/kg) and high (1000 nmol/kg) dose, 30 minutes after a closed-head injury in male Sprague-Dawley rats. Results At postinjury day 3, treatment with R18D at the high dose significantly reduced axonal injury (P = 0.044), whereas the low-dose treatment of R18D showed a trend for reduced axonal injury. Following assessment in the Barnes maze, both doses of R18D treatment appeared to improve learning and memory recovery compared with vehicle treatment at postinjury days 1 and 3, albeit not to a statistically significant level. Rotarod assessment of vestibulomotor recovery did not differ between R18D and the vehicle treatment groups. Conclusions R18D modestly decreased axonal injury only at the highest dose used but had no significant effect on functional recovery. These findings warrant further studies with additional doses to better understand peptide pharmacodynamics and provide information to guide optimal dosing.
Collapse
Affiliation(s)
- Li Shan Chiu
- Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia
- Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, Western Australia, Australia
- Address correspondence to: Li Shan Chiu, Perron Institute for Neurological and Translational Sciences, QEII Medical Centre, 8 Verdun St, RR Block, Nedlands, Western Australia, 6009, Australia.
| | - Ryan S. Anderton
- Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia
- Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, Western Australia, Australia
- School of Heath Sciences, The University Notre Dame Australia, Fremantle, Western Australia, Australia
- Institute for Health Research, The University Notre Dame Australia, Fremantle, Western Australia, Australia
| | - Vince W. Clark
- Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia
- Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, Western Australia, Australia
- Department of Neurosurgery, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, Western Australia, Australia
| | - Jane L. Cross
- Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia
- Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, Western Australia, Australia
- Department of Neurosurgery, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, Western Australia, Australia
| | - Neville W. Knuckey
- Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia
- Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, Western Australia, Australia
- Department of Neurosurgery, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, Western Australia, Australia
| | - Bruno P. Meloni
- Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia
- Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, Western Australia, Australia
- Department of Neurosurgery, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, Western Australia, Australia
| |
Collapse
|
5
|
Meloni BP, Chen Y, Harrison KA, Nashed JY, Blacker DJ, South SM, Anderton RS, Mastaglia FL, Winterborn A, Knuckey NW, Cook DJ. Poly-Arginine Peptide-18 (R18) Reduces Brain Injury and Improves Functional Outcomes in a Nonhuman Primate Stroke Model. Neurotherapeutics 2020; 17:627-634. [PMID: 31833045 PMCID: PMC7283416 DOI: 10.1007/s13311-019-00809-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Poly-arginine peptide-18 (R18) is neuroprotective in different rodent middle cerebral artery occlusion (MCAO) stroke models. In this study, we examined whether R18 treatment could reduce ischemic brain injury and improve functional outcome in a nonhuman primate (NHP) stroke model. A stroke was induced in male cynomolgus macaques by MCAO distal to the orbitofrontal branch of the MCA through a right pterional craniotomy, using a 5-mm titanium aneurysm clip for 90 min. R18 (1000 nmol/kg) or saline vehicle was administered intravenously 60 min after the onset of MCAO. Magnetic resonance imaging (MRI; perfusion-weighted imaging, diffusion-weighted imaging, or T2-weighted imaging) of the brain was performed 15 min, 24 h, and 28 days post-MCAO, and neurological outcome was assessed using the NHP stroke scale (NHPSS). Experimental endpoint was 28 days post-MCAO, treatments were randomized, and all procedures were performed blinded to treatment status. R18 treatment reduced infarct lesion volume by up to 65.2% and 69.7% at 24 h and 28 days poststroke, respectively. Based on NHPSS scores, R18-treated animals displayed reduced functional deficits. This study confirms the effectiveness of R18 in reducing the severity of ischemic brain injury and improving functional outcomes after stroke in a NHP model, and provides further support for its clinical development as a stroke neuroprotective therapeutic.
Collapse
Affiliation(s)
- Bruno P Meloni
- Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, 6009, Australia
- Department of Neurosurgery, QEII Medical Centre, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
- Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Perth, Western Australia, Australia
| | - Yining Chen
- Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada
| | - Kathleen A Harrison
- Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada
| | - Joseph Y Nashed
- Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada
| | - David J Blacker
- Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, 6009, Australia
- Department of Neurosurgery, QEII Medical Centre, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
- Department of Neurology, QEII Medical Centre, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
| | - Samantha M South
- Office of Research Enterprise, The University of Western Australia, Perth, Western Australia, Australia
| | - Ryan S Anderton
- Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, 6009, Australia
- Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Perth, Western Australia, Australia
- School of Heath Sciences, and Institute for Health Research, The University Notre Dame Australia, Fremantle, Australia
| | - Frank L Mastaglia
- Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, 6009, Australia
- Department of Neurosurgery, QEII Medical Centre, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
| | - Andrew Winterborn
- Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada
| | - Neville W Knuckey
- Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, 6009, Australia
- Department of Neurosurgery, QEII Medical Centre, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
- Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Perth, Western Australia, Australia
| | - Douglas J Cook
- Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada.
- Division of Neurosurgery, Department of Surgery, Queen's University Kingston Health Sciences Centre, Kingston, Ontario, Canada.
- Division of Neurosurgery, Department of Surgery, Dalhousie University Halifax, Nova Scotia, Canada.
| |
Collapse
|
6
|
Meloni BP, Mastaglia FL, Knuckey NW. Cationic Arginine-Rich Peptides (CARPs): A Novel Class of Neuroprotective Agents With a Multimodal Mechanism of Action. Front Neurol 2020; 11:108. [PMID: 32158425 PMCID: PMC7052017 DOI: 10.3389/fneur.2020.00108] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Accepted: 01/30/2020] [Indexed: 12/17/2022] Open
Abstract
There are virtually no clinically available neuroprotective drugs for the treatment of acute and chronic neurological disorders, hence there is an urgent need for the development of new neuroprotective molecules. Cationic arginine-rich peptides (CARPs) are an expanding and relatively novel class of compounds, which possess intrinsic neuroprotective properties. Intriguingly, CARPs possess a combination of biological properties unprecedented for a neuroprotective agent including the ability to traverse cell membranes and enter the CNS, antagonize calcium influx, target mitochondria, stabilize proteins, inhibit proteolytic enzymes, induce pro-survival signaling, scavenge toxic molecules, and reduce oxidative stress as well as, having a range of anti-inflammatory, analgesic, anti-microbial, and anti-cancer actions. CARPs have also been used as carrier molecules for the delivery of other putative neuroprotective agents across the blood-brain barrier and blood-spinal cord barrier. However, there is increasing evidence that the neuroprotective efficacy of many, if not all these other agents delivered using a cationic arginine-rich cell-penetrating peptide (CCPPs) carrier (e.g., TAT) may actually be mediated largely by the properties of the carrier molecule, with overall efficacy further enhanced according to the amino acid composition of the cargo peptide, in particular its arginine content. Therefore, in reviewing the neuroprotective mechanisms of action of CARPs we also consider studies using CCPPs fused to a putative neuroprotective peptide. We review the history of CARPs in neuroprotection and discuss in detail the intrinsic biological properties that may contribute to their cytoprotective effects and their usefulness as a broad-acting class of neuroprotective drugs.
Collapse
Affiliation(s)
- Bruno P Meloni
- Department of Neurosurgery, QEII Medical Centre, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.,Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia.,Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, WA, Australia
| | - Frank L Mastaglia
- Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia.,Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, WA, Australia
| | - Neville W Knuckey
- Department of Neurosurgery, QEII Medical Centre, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.,Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia.,Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, WA, Australia
| |
Collapse
|
7
|
In vitro cellular uptake and neuroprotective efficacy of poly-arginine-18 (R18) and poly-ornithine-18 (O18) peptides: critical role of arginine guanidinium head groups for neuroprotection. Mol Cell Biochem 2019; 464:27-38. [DOI: 10.1007/s11010-019-03646-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2019] [Accepted: 10/23/2019] [Indexed: 12/13/2022]
|